40 results about "Gemfibrozil" patented technology

The present invention is process of preparing gemfibrozil medicine powder, and belongs to the field of insoluble medicine micronizing technology. Through dissolving gemfibrozil medicine in water solution of sodium hydroxide, neutralizing and replacing with added water solution of hydrochloric acid containing surfactant to obtain suspension of gemfibrozil medicine, filtering, washing and drying, spheroid gemfibrozil medicine powder in submicron size is produced. The process is simple, low in cost and easy in industrial application, and the obtained gemfibrozil medicine powder has regular shape, narrow size distribution and high dispersivity. The present invention lays foundation for the industrial production and the new preparation form development of gemfibrozil medicine.

The invention relates to a choline salt of a hypolipidemic drug and a preparation method and a pharmaceutical use thereof. The invention provides a choline salt of a class of hypolipidemic drugs, and the hypolipidemic drugs include but not limited to clofibrate, libet, fenofibrate, ciprofibrate, gemfibrozil, acipimox, niacin, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, pitavastatin, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and other unsaturated fatty acids. The choline salt of the hypolipidemic drug can be used for treating hyperlipidemia and other cardiovascular diseases. The invention also provides a preparation method of the choline salt of the hypolipidemic drug.

The invention provides a gemfibrozil hapten and an artificial antigen. Molecular structural formulas of the gemfibrozil hapten and the artificial antigen are correspondingly as shown in the description. The invention further discloses preparation methods for the gemfibrozil hapten, the artificial antigen and an antibody prepared from the gemfibrozil hapten and the artificial antigen and purposes of the gemfibrozil hapten and the antibody. The antibody which is finally prepared by the preparation method provided by the invention has the advantages of high detection sensitivity and high specificity.

The invention discloses a high-purity low-chroma gemfibrozil preparation method. The method comprises 1, preparing a gemfibrozil isobutyl ester crude product and can also comprises 2, adding an alkali liquor II in the gemfibrozil isobutyl ester crude product until the system pH is in a range of 10.0-12 and carrying out reduced pressure rectification to obtain gemfibrozil isobutyl ester, 3, carrying out reflux alkaline hydrolysis on the gemfibrozil isobutyl ester and carrying out acid adjustment to obtain a gemfibrozil crude product, and 4, refining the gemfibrozil crude product through adding an alcohol-water solution into the gemfibrozil crude product, carrying out heating reflux, carrying out heat preservation for 0.5-1h, carrying out cooling to a temperature of 0-5 DEG C, carrying out thermal insulation stirring for 1.5-2.5h, carrying out filtration to obtain filter cake and drying the filter cake to obtain high-purity low-chroma gemfibrozil.

This invention relates to an absorbent including trimethylsilylated mesoporous silica SBA-15, and more particularly to an absorbent including trimethylsilylated mesoporous silica SBA-15, which can effectively remove 90% or more of the seven pharmaceuticals of carbamazepine, diclofenac, estrone, gemfibrozil, ibuprofen, ketoprofen, and trimethoprim which are present in high concentration.

The present invention is process of preparing gemfibrozil medicine powder, and belongs to the field of insoluble medicine micronizing technology. Through dissolving gemfibrozil medicine in water solution of sodium hydroxide, neutralizing and replacing with added water solution of hydrochloric acid containing surfactant to obtain suspension of gemfibrozil medicine, filtering, washing and drying, spheroid gemfibrozil medicine powder in submicron size is produced. The process is simple, low in cost and easy in industrial application, and the obtained gemfibrozil medicine powder has regular shape, narrow size distribution and high dispersivity. The present invention lays foundation for the industrial production and the new preparation form development of gemfibrozil medicine.

The new use of gemfibrozil relates to the field of glioma treatment. Application of the gemfibrozil of the present invention in improving the therapeutic effect of temozolomide on glioma. The application of the gemfibrozil of the present invention in enhancing the killing effect of temozolomide on glioma cells. A pharmaceutical composition for preventing and / or treating glioma of the present invention, the pharmaceutical composition contains gemfibrozil and temozolomide. It has been proved by experiments that gemfibrozil can improve the therapeutic effect of temozolomide on glioma, has synergistic effect of temozolomide on killing glioma cells, and can enhance the killing effect of temozolomide on glioma cells. The preparation of gemfibrozil and temozolomide into a drug for preventing and / or treating glioma can improve the therapeutic effect of temozolomide on glioma. The application of gemfibrozil in the preparation of drugs for the prevention and / or treatment of glioma opens up a new application of gemfibrozil, and provides a new therapy and treatment plan for the treatment of the chronic disease of glioma.

The invention discloses a medicinal composition of gemfibrozil and medicinal application of the medicinal composition. The medicinal composition of gemfibrozil, which is disclosed by the invention, comprises gemfibrozil and a natural product component (I) of a novel structure. When being used independently, gemfibrozil and the compound (I) have protection functions on acute gastric ulcer damage; when being used cooperatively, the protection functions of gemfibrozil and the compound (I) on acute gastric ulcer damage are further enhanced, so that a medicine for treating acute gastric ulcer damage can be developed, and compared with the prior art, the medicinal composition has outstanding substantial characteristics and remarkable improvement.

The invention relates to a composition capable of comprehensively improving blood lipid and insulin resistance state of a body at the same time, and belongs to the field of pharmacy. The composition comprises pharmaceutically acceptable doses of phenoxyaromatic acid drugs (including fenofibrate, bezafibrate, gemfibrozil, etc.) or pharmaceutically acceptable salts thereof, pharmaceutically acceptable doses of taurine and pharmaceutically acceptable carriers or excipients. The present invention also relates to that the composition is used to comprehensively control blood lipids of patients, including reducing total cholesterol (TC), low-density lipoprotein (LDL) and triglyceride (TG), and increasing high-density lipoprotein (HDL); simultaneously the present invention The composition involved can be used to treat metabolic syndrome, synergistically improve the insulin resistance state of the body, and improve the insulin sensitivity index, and its effect is obviously better than that of a single medicine. The present invention also relates to the application of the composition in the preparation of medicines for the treatment of living bodies with dyslipidemia or metabolic syndrome.

The invention provides application of gemfibrozil and pharmaceutically acceptable salt, ester or stereoisomer thereof in preparation of medicines for treating and / or preventing neurodegenerative diseases. The neurodegenerative disease are selected from Alzheimer's disease, Parkinson's disease, Huntington's disease or amyotrophic lateral sclerosis. The invention also provides a pharmaceutical composition for treating and / or preventing the neurodegenerative diseases, wherein the pharmaceutical composition comprises the gemfibrozil, and the pharmaceutically acceptable salt, ester or stereoisomerthereof; and preferably, the pharmaceutical composition further comprises one or more pharmaceutical carriers. The invention also provides application of the pharmaceutical composition containing thegemfibrozil and the pharmaceutically acceptable salt, ester or stereoisomer thereof in preparation of medicines for treating and / or preventing the neurodegenerative diseases.

The invention relates to a gemfibrozil oxime derivative and its use as an FXR antagonist. The invention provides a compound shown in the formula (I) or its pharmaceutically acceptable salt and a preparation method thereof. In the formula, R1 represents hydrogen, hydroxyl, methyl, methoxyl, halogen, or a nitro group, R2 represents hydrogen, hydroxyl, methyl, trifluoromethyl or halogen, R3 represents hydrogen, hydroxyl, methyl, methoxyl, halogen or a nitro group, R4 represents hydrogen or methyl, R5 represents hydrogen or methyl, R6 represents hydrogen or methyl, and X represents NH, O or S. In addition, the compound shown in the formula (I) or its pharmaceutically acceptable salt has pharmacological effects of reducing blood fat and is a FXR antagonist.

The invention relates to gemfibrozil eutectic crystals prepared by a solvent-assisted ball milling method, belonging to the field of drug development. The method comprises the following steps: putting gemfibrozil and a corresponding eutectic crystal synthon in a mole ratio of 1:0.5-1:2 into a ball mill, adding 0.1-0.3 mL of different secondary solvents and a stainless steel milling ball with the diameter of 12mm, and carrying out ball milling under the vibration condition of 1300-1800 r / min for 20-30 minutes; and after finishing the ball milling, naturally drying the test sample in the air, thereby obtaining the gemfibrozil eutectic crystals. The structure of the gemfibrozil eutectic crystals is characterized by powder X-ray diffraction (PXRD), infrared spectrometry (IR), 1H nuclear magnetic resonance (1H NMR), differential scanning calorimetry (DSC), thermogravimetry (TG) and other means. The in-vitro dissolution rate experiment indicates that the solubility of the gemfibrozil eutectic crystals is obviously enhanced by 10.7 times and 132.48 times as compared with the original drug.

The invention discloses a preparation method of gemfibrozil crystal form I, which comprises the following steps: 1), adding 10 g of gemfibrozil into 20-50 ml of ethanol, stirring until gemfibrozil dissolves; 2), crystallizing, selecting Either of the following methods: method 1, add 20±5ml of water dropwise to the gemfibrozil ethanol solution obtained in step 1), after the dropwise addition, cool down to 10±2°C, stir for 1.5 to 2.5 hours, and filter; method 2 . Add dropwise the gemfibrozil ethanol solution obtained in step 1) into a mixed solvent consisting of 12-15ml of water and 6ml of ethanol. After the dropwise addition, cool down to 10-20°C, stir for 1-2 hours, and filter ; 3), the filter cake obtained by filtering in step 2) was vacuum-dried at 40±5° C. for 7-8 hours to obtain Gefibrozil crystal form I. The preparation of the gemfibrozil crystal form I by the method has a high yield and can significantly reduce the environmental protection pressure of enterprises.